BioPiggy is far too dumb to figure this out. Just like how he thought the USMD Study was not a new study, and merely a subset retrospective analysis of Deep C.
This clown lies more than JOHNNY MANZIEL!!!
Insurers will come aboard if HEDIS quality points are assigned to Cologuard.
Insurers receive money from the State (and the Fed) to drive healthcare standards.
Pretty simple Tom.
Please feel free to tell me how much Exact spends on R&D per quarter and how much of that is for the FDA post approval study?
This should be relatively "easy" for you since you have all the answers.
You are wrong.
FDA approval is not the "validation" of the technology that I am talking about.
If that was the case, we would have seen a dramatic increase in revenues since FDA approval of INTERCEPT back in December of 2014.
You need to listen to the Conference Call.
The CEO even spoke about the ARC needing several quarters to validate the technology.
And I quote...."We now have a significant portion of the US market under contract for INTERCEPT and will be working diligently to support these customers as they begin their validation process. Once customers have completed their validations over the NEXT FEW QUARTERS, we expect the revenue contribution from the US to begin in earnest."
I don't believe that any analyst on the Street is at 240,000
Baird is at 217,000
Blair is at 213,000
Canaccord is at 221,000
"the fact that they are scaling back r&d is very telling"
You must not have listened to the CC.
The CFO noted that the majority of the R&D expense for Exact has been in the form of the post-FDA approval study. That begins to taper off.
The issue for the Street is that although these contracts have been signed, the Intercept technology has to be VALIDATED first and that takes several quarters...... before revenue can begin to flow.
This should be nothing new.
It has been mentioned in previous conference calls.
Sonoran, I would say that the TV ads are for BOTH patients and physicians.
Awareness on BOTH sides of the fence. The Docs need to be REMINDED about CG.
And you don't think that Maneesh already knows about these software apps?
One of Exact's large healthcare system clients (Athena) already uses one.
Theranos was a fraudulent lab to begin with. The majority of blood tests were being done the old fashioned way. As a result, CMS is banning them. Meanwhile, ILMN's "Grail" is a pipe-dream. Can't wait to watch them have to go before the USPSTF 4 to 5 years from now with "evidenced based" data that most likely will include a false-positive rate that is a non-starter.
As usual, you are one clueless crow.
You are correct.
Goes from $13 million to $19 million for Q2.
Also, while the field sales reps will remain virtually the same the inside sales force and marketing team will be expanded to the tune of +$3 million for Q2 ($15.0 million).
And that's pretty much where a number of analysts are for the year, it not as low as 213,000
Baird, Canaccord, and William Blair.
Youre funny Cathy.
Tell me, did you give Whitney a reach "around" when you bent him over with your recommendation of shorting EXAS at $14 in April of 2014.... right before it rallied +114%?
You are a genuine idiot.
How old are you kid?
Most of Wall Street has targets that are in the $8 and $9 dollar range like Canaccord and Goldman. No one has targets anywhere close to where you are talking about.